|Bid||161.02 x 800|
|Ask||170.00 x 800|
|Day's range||167.39 - 170.21|
|52-week range||101.81 - 178.64|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||39.90|
|Earnings date||03 May 2021 - 07 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||202.53|
JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.
Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.